Skip to content

Study · Randomized controlled trial · n = 14 · 1995

7 results

Effects of rhIGF-I administration on bone turnover during short-term fasting.

Grinspoon SK, Baum HB, Peterson S, Klibanski A

The Journal of clinical investigation1 Aug 1995Cited by 66 (Europe PMC)

PMID7543494 (opens in a new tab)PMCIDPMC185277 (opens in a new tab)DOI10.1172/jci118137 (opens in a new tab)PepBankPUB-07543494
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In fasting women, rhIGF-I increased osteocalcin, with significantly higher levels than placebo at treatment end.

    In plain wordsIn fasting women, rhIGF-I increased osteocalcin, with higher levels than placebo at treatment end.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseOsteocalcin
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous twice daily · 6 dAs given in this study (human).

    Measurements

    Osteocalcin fold increase with rhIGF-I
    5 fold
    rhIGF-I administration
    Serum osteocalcin
    20.9 ng/ml
    rhIGF-I group, end of treatment
    Serum osteocalcin
    5.9 ng/ml
    placebo group, end of treatment
    Serum osteocalcin +/- uncertainty magnitude (type not stated)
    17.3 ng/ml
    rhIGF-I group, end of treatment, 20.9 +/- 17.3
    Serum osteocalcin +/- uncertainty magnitude (type not stated)
    6.4 ng/ml
    Placebo group, end of treatment, 5.9 +/- 6.4
    P value for serum osteocalcin comparison
    < 0.05 p value
    rhIGF-I versus placebo, end of treatment

    Source sentences

    Summary
    In the second part of the experimental protocol, serum osteocalcin and PICP levels increased 5- and 3-fold, respectively with rhIGF-I administration and were significantly elevated compared with the placebo group at the end of treatment (20.9 +/- 17.3 vs. 5.9 +/- 6.4 ng/ml for osteocalcin [P < 0.05]…
    2 context sentences
    Summary · context
    We therefore studied 14 normal women ages 19-33 (mean, 24 +/- 4 [SD] years) during a complete 10-d fast.
    Summary · context
    After 4 d of fasting, subjects were randomized to receive rhIGF-I or placebo subcutaneously twice a day for 6 d.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In fasting women, rhIGF-I increased PICP, with significantly higher levels than placebo at treatment end.

    In plain wordsIn fasting women, rhIGF-I increased PICP, with higher levels than placebo at treatment end.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreasePICP
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous twice daily · 6 dAs given in this study (human).

    Measurements

    PICP fold increase with rhIGF-I
    3 fold
    rhIGF-I administration
    Serum PICP
    188 ng/ml
    rhIGF-I group, end of treatment
    Serum PICP
    110 ng/ml
    placebo group, end of treatment
    Serum PICP +/- uncertainty magnitude (type not stated)
    45 ng/ml
    rhIGF-I group, end of treatment, 188 +/- 45
    Serum PICP +/- uncertainty magnitude (type not stated)
    37 ng/ml
    Placebo group, end of treatment, 110 +/- 37
    P value for serum PICP comparison
    < 0.05 p value
    rhIGF-I versus placebo, end of treatment

    Source sentences

    Summary
    In the second part of the experimental protocol, serum osteocalcin and PICP levels increased 5- and 3-fold, respectively with rhIGF-I administration and were significantly elevated compared with the placebo group at the end of treatment (20.9 +/- 17.3 vs. 5.9 +/- 6.4 ng/ml for osteocalcin [P < 0.05]…
    2 context sentences
    Summary · context
    We therefore studied 14 normal women ages 19-33 (mean, 24 +/- 4 [SD] years) during a complete 10-d fast.
    Summary · context
    After 4 d of fasting, subjects were randomized to receive rhIGF-I or placebo subcutaneously twice a day for 6 d.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In fasting women, urinary pyridinoline did not change with rhIGF-I.

    In plain wordsIn fasting women, urinary pyridinoline did not change with rhIGF-I.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeUrinary pyridinoline
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous twice daily · 6 dAs given in this study (human).

    Source sentences

    Summary
    In contrast, all four markers of bone resorption, including urinary pyridinoline, deoxypyridinoline, N-telopeptide and hydroxyproline were unchanged with rhIGF-I administration.
    2 context sentences
    Summary · context
    We therefore studied 14 normal women ages 19-33 (mean, 24 +/- 4 [SD] years) during a complete 10-d fast.
    Summary · context
    After 4 d of fasting, subjects were randomized to receive rhIGF-I or placebo subcutaneously twice a day for 6 d.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In fasting women, urinary deoxypyridinoline did not change with rhIGF-I.

    In plain wordsIn fasting women, urinary deoxypyridinoline did not change with rhIGF-I.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeUrinary deoxypyridinoline
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous twice daily · 6 dAs given in this study (human).

    Source sentences

    Summary
    In contrast, all four markers of bone resorption, including urinary pyridinoline, deoxypyridinoline, N-telopeptide and hydroxyproline were unchanged with rhIGF-I administration.
    2 context sentences
    Summary · context
    We therefore studied 14 normal women ages 19-33 (mean, 24 +/- 4 [SD] years) during a complete 10-d fast.
    Summary · context
    After 4 d of fasting, subjects were randomized to receive rhIGF-I or placebo subcutaneously twice a day for 6 d.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In fasting women, urinary N-telopeptide did not change with rhIGF-I.

    In plain wordsIn fasting women, urinary N-telopeptide did not change with rhIGF-I.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeUrinary N-telopeptide
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous twice daily · 6 dAs given in this study (human).

    Source sentences

    Summary
    In contrast, all four markers of bone resorption, including urinary pyridinoline, deoxypyridinoline, N-telopeptide and hydroxyproline were unchanged with rhIGF-I administration.
    2 context sentences
    Summary · context
    We therefore studied 14 normal women ages 19-33 (mean, 24 +/- 4 [SD] years) during a complete 10-d fast.
    Summary · context
    After 4 d of fasting, subjects were randomized to receive rhIGF-I or placebo subcutaneously twice a day for 6 d.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In fasting women, urinary hydroxyproline did not change with rhIGF-I.

    In plain wordsIn fasting women, urinary hydroxyproline did not change with rhIGF-I.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeUrinary hydroxyproline
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous twice daily · 6 dAs given in this study (human).

    Source sentences

    Summary
    In contrast, all four markers of bone resorption, including urinary pyridinoline, deoxypyridinoline, N-telopeptide and hydroxyproline were unchanged with rhIGF-I administration.
    2 context sentences
    Summary · context
    We therefore studied 14 normal women ages 19-33 (mean, 24 +/- 4 [SD] years) during a complete 10-d fast.
    Summary · context
    After 4 d of fasting, subjects were randomized to receive rhIGF-I or placebo subcutaneously twice a day for 6 d.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 07HumanEndogenous levelNon-randomized trialOther

    In normal women, natural IGF-I levels decreased during fasting before rhIGF-I treatment.

    In plain wordsIn normal women, natural IGF-I levels decreased during fasting before rhIGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseIGF-I during fasting
    Study

    n = 14

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Mean IGF-I level
    310 ng/ml
    baseline, before fasting
    Mean IGF-I level
    186 ng/ml
    after fasting
    Mean IGF-I level +/- uncertainty magnitude (type not stated)
    81 ng/ml
    Before fasting, 310 +/- 81
    Mean IGF-I level +/- uncertainty magnitude (type not stated)
    78 ng/ml
    After fasting, 186 +/- 78
    P value for mean IGF-I level decrease
    0.001 p value
    Before versus after fasting

    Source sentences

    Summary
    Mean IGF-I levels decreased from 310 +/- 81 to 186 +/- 78 ng/ml (P = 0.001).
    2 context sentences
    Summary · context
    We therefore studied 14 normal women ages 19-33 (mean, 24 +/- 4 [SD] years) during a complete 10-d fast.
    Summary · context
    After 4 d of fasting, subjects were randomized to receive rhIGF-I or placebo subcutaneously twice a day for 6 d.

    This result measures the body's own IGF-1 (mecasermin). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.